CMPX - CIK 0001738021
The table below shows Compass Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$49.14M | -$44.85M | -$40.62M | -$34.13M | -$19.67M | -$26.80M |
| Capital expenditure | $25.00K | $44.00K | $30.00K | $212.00K | $1.57M | $106.00K |
| Investing cash flow | -$93.31M | $46.77M | $26.96M | -$151.20M | -$1.77M | $38.00K |
| Dividends paid | - | - | - | - | - |
Compass Therapeutics, Inc. reported operating cash flow of -$49.14M for fiscal year 2025. That is down 9.6% from -$44.85M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$32.76K (FY 2019) to -$49.14M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $129.61M | $17.34M | $2.94M | $75.76M | $118.61M | $48.54M |